<?xml version='1.0' encoding='utf-8'?>
<document id="27297005"><sentence text="Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study."><entity charOffset="0-14" id="DDI-PubMed.27297005.s1.e0" text="Bisphosphonate" /><entity charOffset="98-112" id="DDI-PubMed.27297005.s1.e1" text="glucocorticoid" /><pair ddi="false" e1="DDI-PubMed.27297005.s1.e0" e2="DDI-PubMed.27297005.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27297005.s1.e0" e2="DDI-PubMed.27297005.s1.e1" /></sentence><sentence text="The effect of bisphosphonates on extra-osseous tissue is rarely investigated"><entity charOffset="14-29" id="DDI-PubMed.27297005.s2.e0" text="bisphosphonates" /></sentence><sentence text=" We performed an exploratory analysis on the association of new bisphosphonate use and incident tendon rupture in patients with or without oral glucocorticoid co-medication"><entity charOffset="64-78" id="DDI-PubMed.27297005.s3.e0" text="bisphosphonate" /><entity charOffset="144-158" id="DDI-PubMed.27297005.s3.e1" text="glucocorticoid" /><pair ddi="false" e1="DDI-PubMed.27297005.s3.e0" e2="DDI-PubMed.27297005.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27297005.s3.e0" e2="DDI-PubMed.27297005.s3.e1" /></sentence><sentence text="" /><sentence text="We conducted a matched case-control study using data from the UK-based Clinical Practice Research Datalink" /><sentence text=" Cases were patients aged 30-89 years with an incident diagnosis of Achilles or biceps tendon rupture between 1995 and 2013" /><sentence text=" We compared new oral bisphosphonate use between cases and controls with or without oral glucocorticoid co-medication, by timing (last prescription &lt;/≥180 days) and duration (number of prescriptions) of bisphosphonate use"><entity charOffset="22-36" id="DDI-PubMed.27297005.s7.e0" text="bisphosphonate" /><entity charOffset="89-103" id="DDI-PubMed.27297005.s7.e1" text="glucocorticoid" /><entity charOffset="203-217" id="DDI-PubMed.27297005.s7.e2" text="bisphosphonate" /><pair ddi="false" e1="DDI-PubMed.27297005.s7.e0" e2="DDI-PubMed.27297005.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27297005.s7.e0" e2="DDI-PubMed.27297005.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27297005.s7.e0" e2="DDI-PubMed.27297005.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27297005.s7.e1" e2="DDI-PubMed.27297005.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27297005.s7.e1" e2="DDI-PubMed.27297005.s7.e2" /></sentence><sentence text=" In a case-crossover analysis, we compared new bisphosphonate exposure in the event period and the control period controlling for glucocorticoid use"><entity charOffset="47-61" id="DDI-PubMed.27297005.s8.e0" text="bisphosphonate" /><entity charOffset="130-144" id="DDI-PubMed.27297005.s8.e1" text="glucocorticoid" /><pair ddi="false" e1="DDI-PubMed.27297005.s8.e0" e2="DDI-PubMed.27297005.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27297005.s8.e0" e2="DDI-PubMed.27297005.s8.e1" /></sentence><sentence text="" /><sentence text="Among 7859 cases, 246 (3" /><sentence text="1%) were new users of bisphosphonates"><entity charOffset="22-37" id="DDI-PubMed.27297005.s11.e0" text="bisphosphonates" /></sentence><sentence text=" Patients with glucocorticoid co-medication had an odds ratio (OR) for tendon rupture of 6"><entity charOffset="15-29" id="DDI-PubMed.27297005.s12.e0" text="glucocorticoid" /></sentence><sentence text="42 (95%CI 4" /><sentence text="03-10" /><sentence text="22) for short-term bisphosphonate use (≤4 prescriptions), which declined with increasing number of prescriptions"><entity charOffset="19-33" id="DDI-PubMed.27297005.s15.e0" text="bisphosphonate" /></sentence><sentence text=" Among people with continuous prednisone use of 5-10 mg/day, bisphosphonate users with &lt;9 prescriptions had an OR of 2"><entity charOffset="30-40" id="DDI-PubMed.27297005.s16.e0" text="prednisone" /><entity charOffset="61-75" id="DDI-PubMed.27297005.s16.e1" text="bisphosphonate" /><pair ddi="false" e1="DDI-PubMed.27297005.s16.e0" e2="DDI-PubMed.27297005.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27297005.s16.e0" e2="DDI-PubMed.27297005.s16.e1" /></sentence><sentence text="46 (95%CI 1" /><sentence text="00-6" /><sentence text="03), compared with bisphosphonate non-users"><entity charOffset="19-33" id="DDI-PubMed.27297005.s19.e0" text="bisphosphonate" /></sentence><sentence text=" The case-crossover analysis yielded an OR of 4" /><sentence text="46 (95%CI 2" /><sentence text="76-7" /><sentence text="20) for new bisphosphonate treatment in patients with glucocorticoid co-medication, and a null result in glucocorticoid non-users"><entity charOffset="12-26" id="DDI-PubMed.27297005.s23.e0" text="bisphosphonate" /><entity charOffset="54-68" id="DDI-PubMed.27297005.s23.e1" text="glucocorticoid" /><entity charOffset="105-119" id="DDI-PubMed.27297005.s23.e2" text="glucocorticoid" /><pair ddi="false" e1="DDI-PubMed.27297005.s23.e0" e2="DDI-PubMed.27297005.s23.e0" /><pair ddi="false" e1="DDI-PubMed.27297005.s23.e0" e2="DDI-PubMed.27297005.s23.e1" /><pair ddi="false" e1="DDI-PubMed.27297005.s23.e0" e2="DDI-PubMed.27297005.s23.e2" /><pair ddi="false" e1="DDI-PubMed.27297005.s23.e1" e2="DDI-PubMed.27297005.s23.e1" /><pair ddi="false" e1="DDI-PubMed.27297005.s23.e1" e2="DDI-PubMed.27297005.s23.e2" /></sentence><sentence text="" /><sentence text="New bisphosphonate treatment may transiently increase the risk of tendon rupture in oral glucocorticoid users"><entity charOffset="4-18" id="DDI-PubMed.27297005.s25.e0" text="bisphosphonate" /><entity charOffset="89-103" id="DDI-PubMed.27297005.s25.e1" text="glucocorticoid" /><pair ddi="false" e1="DDI-PubMed.27297005.s25.e0" e2="DDI-PubMed.27297005.s25.e0" /><pair ddi="false" e1="DDI-PubMed.27297005.s25.e0" e2="DDI-PubMed.27297005.s25.e1" /></sentence><sentence text=" Further research is needed to establish causality of this yet unreported adverse drug reaction or drug-drug interaction" /><sentence text=" Copyright © 2016 John Wiley &amp; Sons, Ltd" /><sentence text="" /></document>